Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchIbuzatrelvirIbuzatrelvir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19

Mortezavi et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae529, NCT05799495
Nov 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Viral load, 600mg, day 5 27% Improvement Relative Risk Viral load, 300mg, day 5 20% Viral load, 100mg, day 5 18% Viral load, 600mg, day 3 48% Viral load, 300mg, day 3 48% Viral load, 100mg, day 3 35% Ibuzatrelvir  Mortezavi et al.  EARLY TREATMENT  DB RCT Is early treatment with ibuzatrelvir beneficial for COVID-19? Double-blind RCT 133 patients in the USA (May - September 2023) Improved viral clearance with ibuzatrelvir (p=0.0001) c19early.org Mortezavi et al., Clinical Infectious .., Nov 2024 Favorsibuzatrelvir Favorscontrol 0 0.5 1 1.5 2+
RCT 240 outpatients showing significant viral load reduction with ibuzatrelvir (an oral SARS-CoV-2 Mpro inhibitor) compared to placebo. The study enrolled non-hospitalized adults aged 18-65 with symptomatic COVID-19 (≤5 days) and positive rapid antigen test, excluding those with obesity, smoking, chronic conditions, or immunocompromised status. Patients were randomized 1:1:2:2 to receive 100mg, 300mg, or 600mg ibuzatrelvir or placebo twice daily for 5 days. There were dose-dependent decreases in viral load at days 3 and 5 compared to placebo. The trial has limited generalizability due to strict exclusion criteria that eliminated many high-risk patients who would typically be candidates for antiviral therapy.
viral load, 27.3% lower, relative load 0.73, p < 0.001, treatment 66, control 60, 600mg, day 5.
viral load, 20.0% lower, relative load 0.80, p = 0.01, treatment 24, control 60, 300mg, day 5.
viral load, 17.9% lower, relative load 0.82, p = 0.02, treatment 34, control 60, 100mg, day 5.
viral load, 48.0% lower, relative load 0.52, p < 0.001, treatment 70, control 63, 600mg, day 3.
viral load, 48.0% lower, relative load 0.52, p < 0.001, treatment 27, control 63, 300mg, day 3.
viral load, 35.0% lower, relative load 0.65, p = 0.01, treatment 35, control 63, 100mg, day 3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mortezavi et al., 2 Nov 2024, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, 13 authors, study period 24 May, 2023 - 8 September, 2023, trial NCT05799495 (history). Contact: mahta.mortezavi@pfizer.com, niki.alami@pfizer.com.
This PaperIbuzatrelvirAll
Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-cov-2 Antiviral, in Adults With COVID-19
MD Mahta Mortezavi, PhD Abigail Sloan, Ravi Shankar, PhD P Singh, MBBS Luke F Chen, PhD Jin Hyang Kim, PhD Negin Shojaee, MD Sima S Toussi, PhD John Prybylski, PhD Mary Lynn Baniecki, PhD Arthur Bergman, PhD Anindita Banerjee, MPhil Charlotte Allerton, MD Negar Niki Alami, Dr Niki Negar, Alami, Head
doi:10.1093/cid/ciae5291
Background: Despite effective vaccines and treatments for COVID-19, clinical burden persists. An unmet need exists for additional effective agents with safety profiles allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 M pro inhibitor that has demonstrated in vitro antiviral activity and low potential for safety concerns, including drug-drug interactions. Methods: This phase 2b, double-blind, randomized clinical trial enrolled US adults aged 18-<65 years with symptomatic COVID-19 and no risk factors for severe disease. Participants were randomized 1:1:2:2 to receive 100, 300, or 600 mg ibuzatrelvir or placebo orally twice daily for 5 days. Nasopharyngeal specimens were collected on Days 1 (baseline), 3, 5, 10, 14, and 21; adverse
Conflict of Interest Disclosures: All authors are employees of Pfizer and may hold stock or stock options.
References
Aggarwal, Molina, Beaty, Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study, Lancet Infect Dis, doi:10.1016/S1473-3099(23)00011-7
Akinosoglou, Rigopoulos, Schinas, Remdesivir use in the real-world setting: an overview of available evidence, Viruses, doi:10.3390/v15051167
Allerton, Arcari, Aschenbrenner, A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19, J Med Chem, doi:10.1021/acs.jmedchem.3c02469
Berg, Zhen, Lucic, Development of the RealTime SARS-CoV-2 quantitative Laboratory Developed Test and correlation with viral culture as a measure of infectivity, J Clin Virol, doi:10.1016/j.jcv.2021.104945
Borroto-Esoda, Wilfret, Tong, Plummer, Kearney et al., SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir, Microbiol Spectr, doi:10.1128/spectrum.02980-23
Boyapati, Wipperman, Ehmann, Baseline severe acute respiratory syndrome viral load is associated with coronavirus disease 2019 severity and clinical outcomes: post hoc analyses of a phase 2/3 trial, J Infect Dis, doi:10.1093/infdis/jiab445
Brnic, Buric, Marcec, Likic, The relationship between vaccine acceptance and COVID-19 mortality in Europe: A Cross-Country analysis of public opinion and Epidemiological data, Vaccine X, doi:10.1016/j.jvacx.2023.100391
Cao, Wang, Lu, Oral simnotrelvir for adult patients with mild-to-moderate Covid-19, N Engl J Med, doi:10.1056/NEJMoa2301425
Gerhart, Draica, Benigno, Real-world evidence of the top 100 prescribed drugs in the USA and their potential for drug interactions with nirmatrelvir; ritonavir, AAPS J, doi:10.1208/s12248-023-00832-3
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Hanrath, Payne, Duncan, Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection, J Infect, doi:10.1016/j.jinf.2020.12.023
Harrington, Cong, Troy, Evaluation of SARS-CoV-2 RNA rebound after nirmatrelvir/ritonavir treatment in randomized, double-blind, placebo-controlled trials -United States and International Sites, 2021-2022, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7251a2
Jain, Serisier, Lorgelly, The real-world impact of vaccination on COVID-19 cases during Europe's Fourth Wave, Int J Public Health, doi:10.3389/ijph.2022.1604793
Jones, Manrique, Stone, Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status -United States, April 2021-September 2022, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7222a3
Li, Hilgenfeld, Whitley, Clercq, Therapeutic strategies for COVID-19: progress and lessons learned, Nat Rev Drug Discov, doi:10.1038/s41573-023-00672-y
Magleby, Westblade, Trzebucki, Impact of severe acute respiratory syndrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019, Clin Infect Dis, doi:10.1093/cid/ciaa851
Monach, Anand, Fillmore, La, Branch-Elliman, Underuse of antiviral drugs to prevent progression to severe COVID-19 -Veterans Health Administration, March-September 2022, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7303a2
Mukae, Yotsuyanagi, Ohmagari, Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study, Clin Infect Dis, doi:10.1093/cid/ciac933
Sahasrabudhe, Mortezavi, Toussi, The SARS-CoV-2 Mpro Inhibitor Ibuzatrelvir is a Substrate but not an Inducer nor Inhibitor of CYP3A, American College of Clinical Pharmacology
Satapathy, Kumar, Mehta, Global spread of COVID-19's JN.1 variant: implications and public health responses, New Microbes New Infect, doi:10.1016/j.nmni.2024.101225
Singh, Toussi, Hackman, Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir, Clin Pharmacol Ther, doi:10.1002/cpt.2603
Smith, Lambrou, Patel, SARS-CoV-2 rebound with and without use of COVID-19 oral antivirals, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7251a1
Standing, Buggiotti, Guerra-Assuncao, Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients, Nat Commun, doi:10.1038/s41467-024-45641-0
Tuttle, Discovery of PF-07817883: A next generation oral protease inhibitor for the treatment of COVID-19, American Chemical Society Fall
Wagenhauser, Knies, Hofmann, Virus variant-specific clinical performance of SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January 2022, Clin Microbiol Infect, doi:10.1016/j.cmi.2022.08.006
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Westblade, Brar, Pinheiro, SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19, Cancer Cell, doi:10.1016/j.ccell.2020.09.007
Yamana, Galanti, Pei, The impact of COVID-19 vaccination in the US: averted burden of SARS-COV-2-related cases, hospitalizations and deaths, PLoS One, doi:10.1371/journal.pone.0275699
{ 'indexed': { 'date-parts': [[2024, 11, 2]], 'date-time': '2024-11-02T04:14:23Z', 'timestamp': 1730520863973, 'version': '3.28.0'}, 'reference-count': 0, 'publisher': 'Oxford University Press (OUP)', 'license': [ { 'start': { 'date-parts': [[2024, 11, 1]], 'date-time': '2024-11-01T00:00:00Z', 'timestamp': 1730419200000}, 'content-version': 'am', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Despite effective vaccines and treatments for COVID-19, clinical ' 'burden persists. An unmet need exists for additional effective agents with safety profiles ' 'allowing use across a broad population. Ibuzatrelvir is an orally bioavailable SARS-CoV-2 ' 'Mpro inhibitor that has demonstrated in vitro antiviral activity and low potential for safety ' 'concerns, including drug-drug interactions.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>This phase 2b, double-blind, randomized clinical trial enrolled US ' 'adults aged 18‒&amp;lt;65 years with symptomatic COVID-19 and no risk factors for severe ' 'disease. Participants were randomized 1:1:2:2 to receive 100, 300, or 600 mg ibuzatrelvir or ' 'placebo orally twice daily for 5 days. Nasopharyngeal specimens were collected on Days 1 ' '(baseline), 3, 5, 10, 14, and 21; adverse events (AEs) were recorded through Day 33. The ' 'primary endpoint was change in SARS-CoV-2 RNA level (viral load [VL]) from baseline to Day 5 ' 'among participants with baseline VL ≥4 log10 copies/mL.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Of 240 enrollees, 237 received ≥1 dose and 199 were included in the ' 'primary analysis. Placebo-adjusted least squares mean (80% CI) change from baseline in VL at ' 'Day 5 was significant across all doses: 100 mg, ‒0.7 (‒1.1, ‒0.3) log10 copies/mL, P=0.02; ' '300 mg, ‒0.8 (‒1.3, ‒0.3) log10 copies/mL, P=0.01; and 600 mg, ‒1.2 (‒1.5, ‒0.8) log10 ' 'copies/mL, P&amp;lt;0.0001. AEs occurred in similar percentages of participants across ' 'groups. No deaths from any cause or treatment-related serious AEs occurred through Day 33, ' 'and no participants reported dysgeusia.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>All 3 ibuzatrelvir doses were associated with robust antiviral ' 'activity and an acceptable safety profile, supporting continued clinical ' 'development.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Trial Registration</jats:title>\n' ' <jats:p>Clinicaltrials.gov identifier: NCT05799495</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/cid/ciae529', 'type': 'journal-article', 'created': {'date-parts': [[2024, 11, 1]], 'date-time': '2024-11-01T22:22:57Z', 'timestamp': 1730499777000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With ' 'COVID-19', 'prefix': '10.1093', 'author': [ { 'given': 'Mahta', 'family': 'Mortezavi', 'sequence': 'first', 'affiliation': [{'name': 'Pfizer Inc , New York, NY ,', 'place': ['USA']}]}, { 'given': 'Abigail', 'family': 'Sloan', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Cambridge, MA ,', 'place': ['USA']}]}, { 'given': 'Ravi Shankar P', 'family': 'Singh', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Cambridge, MA ,', 'place': ['USA']}]}, { 'given': 'Luke F', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Cambridge, MA ,', 'place': ['USA']}]}, { 'given': 'Jin Hyang', 'family': 'Kim', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Collegeville, PA ,', 'place': ['USA']}]}, { 'given': 'Negin', 'family': 'Shojaee', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Cambridge, MA ,', 'place': ['USA']}]}, { 'given': 'Sima S', 'family': 'Toussi', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Pearl River, NY ,', 'place': ['USA']}]}, { 'given': 'John', 'family': 'Prybylski', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Groton, CT ,', 'place': ['USA']}]}, { 'given': 'Mary Lynn', 'family': 'Baniecki', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Cambridge, MA ,', 'place': ['USA']}]}, { 'given': 'Arthur', 'family': 'Bergman', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Groton, CT ,', 'place': ['USA']}]}, { 'given': 'Anindita', 'family': 'Banerjee', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Cambridge, MA ,', 'place': ['USA']}]}, { 'given': 'Charlotte', 'family': 'Allerton', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , Cambridge, MA ,', 'place': ['USA']}]}, { 'given': 'Negar Niki', 'family': 'Alami', 'sequence': 'additional', 'affiliation': [{'name': 'Pfizer Inc , New York, NY ,', 'place': ['USA']}]}], 'member': '286', 'published-online': {'date-parts': [[2024, 11, 2]]}, 'container-title': 'Clinical Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae529/60298252/ciae529.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae529/60298252/ciae529.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 11, 1]], 'date-time': '2024-11-01T22:22:57Z', 'timestamp': 1730499777000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae529/7863440'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 11, 2]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1093/cid/ciae529', 'relation': {}, 'ISSN': ['1058-4838', '1537-6591'], 'subject': [], 'published': {'date-parts': [[2024, 11, 2]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit